RB1 and neoplasm: Cancer cells that were intrinsically lacking of RB or harbored inactivation of this tumor suppressor were implicated to fail to effectively response to palbociclib treatment [36, 60, 79], probably due to the absence of the target for palbociclib in the RB-deficient tumor cell lines [38].